Pulse Biosciences (NASDAQ:PLSE) Trading 5.3% Higher - Still a Buy?

Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) traded up 5.3% on Tuesday . The stock traded as high as $20.54 and last traded at $20.18. 20,155 shares were traded during trading, a decline of 90% from the average session volume of 200,547 shares. The stock had previously closed at $19.17.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research note on Thursday, December 12th.

Pulse Biosciences Stock Performance

The company has a 50 day simple moving average of $17.74 and a 200 day simple moving average of $16.50.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same quarter last year, the company earned ($0.19) EPS.

Insiders Place Their Bets

In related news, Director Robert W. Duggan bought 56,054 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was acquired at an average cost of $17.35 per share, with a total value of $972,536.90. Following the transaction, the director now directly owns 42,228,057 shares in the company, valued at approximately $732,656,788.95. This trade represents a 0.13 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 71.50% of the company's stock.

Hedge Funds Weigh In On Pulse Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in PLSE. Charles Schwab Investment Management Inc. increased its stake in shares of Pulse Biosciences by 193.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company's stock valued at $2,598,000 after acquiring an additional 97,565 shares in the last quarter. State Street Corp boosted its position in shares of Pulse Biosciences by 17.8% during the 3rd quarter. State Street Corp now owns 461,333 shares of the company's stock worth $8,092,000 after purchasing an additional 69,696 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Pulse Biosciences in the 3rd quarter valued at about $588,000. Geode Capital Management LLC increased its position in Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company's stock valued at $8,020,000 after buying an additional 33,200 shares in the last quarter. Finally, Barclays PLC raised its stake in Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company's stock worth $530,000 after buying an additional 23,738 shares during the period. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.